2020 Scientific Retreat- Session 4

Session 4: Late Breaking Clinical Data for Prostate Cancer Patients 

8:05 AM – 9:20 AM 

Moderators:  
Howard Soule, PhD 
Prostate Cancer Foundation 

Introduction 
Howard Soule, PhD 
Prostate Cancer Foundation 

Combinatorial Targeting of AR and AKT with Abiraterone and Ipatasertib for mCRPC with and without PTEN loss: The Ipatential150 Phase 3 Trial 
Johann de Bono, MD, PhD 
The Institute of Cancer Research; Royal Marsden Hospital, London, UK 

Phase 1 Clinical Profile of AMG 160, a Half-Life Extended PSMA Bispecific T-cell Engager (BiTE®) Immunotherapy for Patients with Metastatic Castration-Resistant Prostate Cancer 
Matthew Rettig, MD 
University of California, Los Angeles; VA Greater Los Angeles Healthcare System 

Phase 1 Study of AMG 509, a STEAP1 x CD3 T Cell–Recruiting XmAb® 2+1 Immune Therapy, in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) 
Wm. Kevin Kelly, DO 
Sidney Kimmel Medical College at Thomas Jefferson University; Sidney Kimmel Cancer Center 

Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy: Focus in Prostate Cancer 
Dimitris Skokos, PhD 
Regeneron Pharmaceuticals 

Elizabeth Miller, MD 
Regeneron Pharmaceuticals 

Live Session Discussion 

9:20 AM – 9:25 AM     Please Return to the Virtual Lobby to Join the Next Session